Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension

Key facts

Sponsor

Nanjing First Hospital, Nanjing Medical University

Principal Investigator

Hang Zhang, MD

Nanjing First Hospital, Nanjing Medical University

Intervention

PADN(procedure)

Enrollment

128 enrolled

Eligibility

18 years · All sexes

Timeline

2018 – 2021

Study locations (1)

• Nanjing First Hospital, Nanjing, Jiangsu, China

Collaborators

Pulnovo Medical (Wuxi) Co., Ltd. · Guangdong Provincial People's Hospital · The First Affiliated Hospital of Zhengzhou University · Tianjin Medical University General Hospital · First Affiliated Hospital Xi'an Jiaotong University · Beijing Anzhen Hospital · Shenyang Northern Hospital · The Second Affiliated Hospital of Chongqing Medical University · Tongji Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07529821
  Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive Patients
  Foundation University Islamabad
• ACTIVE NOT RECRUITINGNCT07312227
  A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia
  Massachusetts General Hospital
• ENROLLING BY INVITATIONNANCT07558460
  Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled Trial
  Istanbul University - Cerrahpasa
• RECRUITINGPHASE2NCT07318597
  Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
  Regeneron Pharmaceuticals
• RECRUITINGPHASE1NCT06872112
  A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
  Joseph C. Wu
• RECRUITINGPHASE2NCT06351345
  129 Xenon Imaging in Patients Treated With Sotatercept
  Bastiaan Driehuys
• RECRUITINGPHASE4NCT07140484
  Sotatercept in Pulmonary Arterial Hypertension
  University of Alberta
• RECRUITINGPHASE2NCT07175038
  A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
  AllRock Bio, Inc.

See all trials for Drug- or toxin-induced pulmonary arterial hypertension →